Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > ORGANIZATION
ORGANIZATION
- Japan Digital Health Alliance Keen to Boost Ties with Overseas Organizations
June 21, 2024
- JGA to Establish Study Group on Generic Industry Realignment
June 21, 2024
- Majority of Candidates for G1 Withdrawal Scheme Not Able to Exit Market: FPMAJ Survey
June 17, 2024
- FPMAJ Hails 2024 Reform, but Frets No Mention of Scrapping Off-Year Cuts in Honebuto Draft
June 17, 2024
- EFPIA Japan Issues New Proposal on HTA, Calls for Transparency
June 10, 2024
- 135 Meds Still in Lag/Loss State in Japan, JPMA Task Force Revving Up Fight
June 5, 2024
- JPMA Pushing Industry-Academia Consortia in Non-Competitive Drug Discovery Fields
June 5, 2024
- JPMA, PhRMA, EFPIA to Jointly Survey Views on 2024 Drug Pricing Reform
May 24, 2024
- New Task Force Discussing Steps to Stem Further Increase in Drug Lag/Loss: JPMA
April 30, 2024
- JPMA Eager to Work with Regulators to Improve Guidance on Orphan Meds, PI Trials
April 30, 2024
- Policymakers Prod for Industry’s Concrete Actions Toward Eliminating Drug Loss
April 24, 2024
- Govt Should Buy Up Domestic Antibiotic APIs, Cost 5-8 Times Higher: Industry Official
April 24, 2024
- JPMA Reiterates Opposition to Off-Year Revisions towards Honebuto 2024
April 19, 2024
- Doctors’ Lobby Objects MOF Proposal for CEA Use in Reimbursement Decisions
April 18, 2024
- Only 3 Prefectures Log “Below 80%” Generic Rate in November: Kyokai Kenpo
April 10, 2024
- JPMA Launches Website Listing R&D Policies of Members to Help Foster Innovation Ecosystem
April 9, 2024
- New LLP Coverage Scheme Intended for Generic Promotion: Payer Exec
April 8, 2024
- Generic Rate Hits Record for 6th Straight Quarter in October-December: JGA
April 8, 2024
- PhRMA Hails 2024 Reform, but Says Full Picture Unchanged as 50% of Patented Meds Still Face Cuts
April 4, 2024
- Pharma Labor Group Makes Direct Plea to Lawmakers against Off-Year Price Cuts
April 3, 2024
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…